Based on this YouTube video's total view count of 831 views and industry-standard rates, the estimated total earning is $1 - $2 through ad revenue. Historical data is not yet available to calculate daily, weekly, or monthly averages.

Explore KRd vs VRd as Induction Therapy in Newly Diagnosed High-Risk Multiple Myeloma with 831 views, 12 likes, and 1 comments. Experience the impact of this video content that has captured audience attention.

Dr. Carlyn Tan, Memorial Sloan Kettering Cancer Center, presents the results of a study on Carfilzomib, Lenalidomide and Dexamethasone (KRd) Vs Bortezomib, Lenalidomide, and Dexamethasone (VRd) as induction therapy in newly diagnosed High-Risk Multiple Myeloma (HR-NDMM). Background: Bortezomib, lenalidomide, dexamethasone (VRd) and carfilzomib, lenalidomide, dexamethasone (KRd) are standard induction regimens for the treatment of newly diagnosed multiple myeloma (NDMM). The phase III ENDURANCE trial excluded patients with high-risk NDMM (HR-NDMM) and included patients with no intention for immediate autologous stem cell transplant (ASCT) (Kumar SK, et al. Lancet Oncol 2020). Herein, we examined outcomes associated with KRd and VRd induction in the management of HR-NDMM. Conclusions: There was a significant improvement in PFS among HR-NDMM patients who received KRd compared to VRd induction. In patients who received early ASCT, we did not observe a statistically significant difference in PFS or OS between the two induction regimens, but this analysis is subject to inherent selection bias. Until results from prospective randomized studies are available for HR-NDMM patients, the use of various induction regimens in transplant-eligible patients opting for early transplant should be tailored to each patient. Authors: Carlyn Tan, MD1, David Nemirovsky, MS2*, Andriy Derkach, PhD2*, Malin Hultcrantz, MD, PhD1, Hani Hassoun, MD1, Sham Mailankody, MBBS 3, Urvi A Shah, MD1, Dhwani Patel, MD1*, Kylee H Maclachlan, MBBCh, PhD1, Oscar B Lahoud, MD3, Gunjan L. Shah, MD3*, Michael Scordo, MD3, David J. Chung, MD, PhD3, Heather Landau, MD3, Sergio A Giralt, MD3, Alexander M Lesokhin, MD1, Neha Korde, MD1 and Saad Usmani, MD4,5 ASH Abstract #752: https://ash.confex.com/ash/2022/webprogram/Paper169161.html _______________ Improving Lives | Finding the Cure Founded in 1990, the International Myeloma Foundation (IMF) is the first and largest organization focusing specifically on multiple myeloma. The IMF’s reach extends to more than 525,000 members in 140 countries worldwide. The IMF is dedicated to improving the quality of lives of myeloma patients while working toward prevention and a cure through our four founding principles: Research, Education, Support, and Advocacy. Subscribe to our channel: https://www.youtube.com/c/IMFMyeloma Visit our website at: https://www.myeloma.org Find us online: Facebook: @myeloma | https://facebook.com/myeloma Twitter: @IMFMyeloma | https://twitter.com/IMFmyeloma Instagram: @imfmyeloma | https://www.instagram.com/imfmyeloma LinkedIn: https://www.linkedin.com/company/international-myeloma-foundation Support the IMF | Donate Now! https://secure.myeloma.org/page/40697/donate/1 Category Nonprofits & Activism License Standard YouTube License In most cases, captions are autogenerated by YouTube.

With SocialCounts.org’s view counter, track your YouTube video’s live view count and YouTube likes count in real time with fast, reliable updates.

Watch every YouTube video live view count rise with our real-time YouTube views tracker—built for accuracy and minimal delay.

Follow YouTube real time views as they happen, using our dedicated view counter for YouTube videos.

Get up-to-date live view count on YouTube and see real-time growth with SocialCounts.org’s smart tracking tools.